论文部分内容阅读
近年来的研究证明,在急性粒细胞性白血病(下称急粒),经过化疗可获得约一半的完全缓解率,但单独化疗不能维持长期缓解。本文探讨了急粒患者在缓解期应用免疫治疗对缓解时间及生存期的影响。免疫疗法的科学基础试用各种不同的免疫学方法来影响人类肿瘤的病程,已有80多年的历史,但关于临床应用,迄今只有少数报告。动物实验和临床研究说明急性白血病患者用照射的白血病细胞自身免疫后,再测定其免疫学反应发现有所改变。根据以往的报告,免疫治疗的剂量需要经常(每1～2周)注射
In recent years, studies have shown that in acute myeloid leukemia (hereinafter referred to as acute particles), after chemotherapy can get about half of the complete remission rate, but chemotherapy alone can not maintain long-term relief. This article explores the impact of immunosuppressive therapy on response time and survival in acute pelleting patients during remission. The Scientific Basis of Immunotherapy There are over 80 years of trials that have used different immunological approaches to influence the course of human cancers, but so far few have been reported for clinical use. Animal experiments and clinical studies show that acute leukemia patients with irradiated leukemia cells after autoimmunity, and then determine the immunological response was found to change. According to previous reports, the dose of immunotherapy requires frequent (every 1 to 2 weeks) injections